SUDEEPPHRM Share Price | Sudeep Pharma Ltd Stock Analysis & Recommendation

Q: When is the next results date for Sudeep Pharma Ltd?

The next results date for Sudeep Pharma Ltd is scheduled for 21 May 2026.

Q: Should I buy, sell or hold Sudeep Pharma Ltd?

Based on the current analysis of Sudeep Pharma Ltd, it would be advisable to hold your position in the company. The firm demonstrates high management efficiency with a notable return on equity (ROE) of 19.6%, indicating effective use of equity capital. Additionally, the company has a strong ability to service its debt, reflected in a low Debt to EBITDA ratio of 0.68 times.Recent quarterly results show promising performance, with net sales reaching their highest at Rs 182.34 crore and a significant increase in profit before tax. However, it's important to note that the company has experienced poor long-term growth, with operating profit stagnating at an annual growth rate of 0% over the past five years.Despite the positive short-term financial results, the valuation appears expensive with a Price to Book Value of 8.6, which may raise concerns for potential investors. Given these factors, maintaining your current position seems prudent until there are clearer signs of sustainable growth or a more favorable valuation.

Q: Why is Sudeep Pharma Ltd falling/rising?

As of 02-Jun, Sudeep Pharma Ltd's stock price is currently at 776.35, reflecting a decrease of 6.6 points or 0.84%. This decline comes after a trend reversal, as the stock had experienced two consecutive days of gains prior to today. The stock's performance today has underperformed the sector by 0.34%. Despite the current drop, Sudeep Pharma has shown strong performance over the past week and month, with increases of 11.59% and 9.64%, respectively. Year-to-date, the stock has risen by 28.87%, significantly outperforming the Sensex, which has decreased by 12.40% during the same period. Today's trading saw the stock reach an intraday high of Rs 811, which was a 3.58% increase, but it also touched a low of Rs 766.6, indicating volatility within the trading session. The weighted average price suggests that more volume was traded closer to the low price, indicating some selling pressure. Investor participation has increased, with a delivery volume of 6.05 lacs on June 1, up by 197.99% compared to the five-day average, suggesting that while there is interest in the stock, the current selling pressure has led to the decline in price today. Overall, while Sudeep Pharma Ltd has demonstrated strong performance metrics and management efficiency, the stock's current fall can be attributed to a combination of a trend reversal after previous gains, underperformance relative to the sector today, and intraday volatility.

Results Declared: Sudeep Pharma has declared results on 21 May 2026! Click here to unlock the latest financial performance

Mojo Score Change: Sudeep Pharma has changed its score on 22 May 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.51 lacs (-66.68%) Volume

Shareholding (Mar 2026)

FII

1.55%

Held by 13 FIIs

DII

18.11%

Held by 10 DIIs

Promoter

76.15%

When is the next results date for Sudeep Pharma Ltd?

15-May-2026

The next results date for Sudeep Pharma Ltd is 21 May 2026.

View full answer

Should I buy, sell or hold Sudeep Pharma Ltd?

23-May-2026

Why is Sudeep Pharma Ltd falling/rising?

03-Jun-2026

As of 02-Jun, Sudeep Pharma Ltd's stock price is at 776.35, down 0.84% after a trend reversal. Despite today's decline, the stock has shown strong performance over the past week and month, with year-to-date gains significantly outperforming the Sensex.

View full answer

Which are the latest news on Sudeep Pharma?

03-Jun-2026

Sudeep Pharma Ltd Locks at Upper Circuit With 10% Gain — Buyers Queue, Sellers Absent
Broad-Based Technical Strength Lifts Sudeep Pharma Ltd to 52-Week High of Rs 815.85

Compare Sudeep Pharma with Similar Stocks

Shilpa Medicare Supriya Lifesci.P & G Health Ltd

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 0%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.68 times

Poor long term growth as Operating profit has grown by an annual rate 0% of over the last 5 years

Positive results in Mar 26

With ROE of 19.6, it has a Very Expensive valuation with a 9.8 Price to Book Value

Majority shareholders : Promoters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 8,726 Cr (Small Cap)

P/E

50.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.04

Return on Equity

19.57%

Price to Book

9.91

Revenue and Profits:

Net Sales:

182 Cr

(Quarterly Results - Mar 2026)

Net Profit:

49 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

27.66%

6 Months

11.86%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Sudeep Pharma for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Sudeep Pharma Ltd Locks at Upper Circuit With 10% Gain — Buyers Queue, Sellers Absent

At Rs 816.35, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Sudeep Pharma Ltd locked at its upper circuit of 10% on 1 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Broad-Based Technical Strength Lifts Sudeep Pharma Ltd to 52-Week High of Rs 815.85

With a decisive surge to Rs 815.85 on 1 Jun 2026, Sudeep Pharma Ltd has reached a new 52-week and all-time high, propelled by a confluence of strong technical signals and sustained price momentum.

Read full news article

Sudeep Pharma Ltd Surges 7.84% to Day's High of Rs 815.85 — Outperforms Sector by 7.65 Percentage Points

The Sensex edged up by a modest 0.15% on 1 Jun 2026, while Sudeep Pharma Ltd surged 7.84%, marking a standout session in the Pharmaceuticals & Biotechnology sector with a 7.65 percentage-point outperformance. This sharp intraday gain rewrites the short-term narrative for the small-cap stock, which also hit a new 52-week and all-time high of Rs 815.85 during the day.

Read full news article

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

28-May-2026 | Source : BSE

Submission of Earnings Call Transcript for Q4 FY26.

Compliances-Reg.24(A)-Annual Secretarial Compliance

27-May-2026 | Source : BSE

Submission of Annual Secretarial Compliance Report for FY 2025-26

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

23-May-2026 | Source : BSE

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 as amended from time to time we herewith submit the participation of Company Officials in various Investor Conferences in Mumbai as annexed.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

33.98

Debt to EBITDA (avg)

0.72

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.65

Tax Ratio

23.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.67%

ROCE (avg)

24.88%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

9.80

EV to EBIT

41.95

EV to EBITDA

39.15

EV to Capital Employed

9.45

EV to Sales

13.53

PEG Ratio

Dividend Yield

ROCE (Latest)

22.53%

ROE (Latest)

19.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 14 Schemes (6.19%)

FIIs

Held by 13 FIIs (1.55%)

Promoter with highest holding

Riva Resources Private Limited (40.35%)

Highest Public shareholder

Nuvama Crossover Opportunities Fund - Series Iii (3.42%)

Individual Investors Holdings

3.11%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -11.20% vs 2.73% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -4.09% vs -9.65% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "80.17",
          "val2": "90.28",
          "chgp": "-11.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "28.89",
          "val2": "29.61",
          "chgp": "-2.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.97",
          "val2": "0.63",
          "chgp": "212.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "25.77",
          "val2": "26.87",
          "chgp": "-4.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.04%",
          "val2": "32.80%",
          "chgp": "3.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "168.06",
          "val2": "168.40",
          "chgp": "-0.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "61.27",
          "val2": "60.03",
          "chgp": "2.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.47",
          "val2": "1.99",
          "chgp": "74.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "54.95",
          "val2": "41.98",
          "chgp": "30.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.46%",
          "val2": "35.65%",
          "chgp": "0.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "258.34",
          "val2": "251.88",
          "chgp": "2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "90.88",
          "val2": "86.49",
          "chgp": "5.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "3.24",
          "chgp": "26.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "81.82",
          "val2": "62.61",
          "chgp": "30.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "35.18%",
          "val2": "34.34%",
          "chgp": "0.84%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "642.26",
          "val2": "502.00",
          "chgp": "27.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "221.91",
          "val2": "189.95",
          "chgp": "16.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "5.85",
          "chgp": "29.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "172.89",
          "val2": "138.73",
          "chgp": "24.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.55%",
          "val2": "37.84%",
          "chgp": "-3.29%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

80.17

90.28

-11.20%

Operating Profit (PBDIT) excl Other Income

28.89

29.61

-2.43%

Interest

1.97

0.63

212.70%

Exceptional Items

0.00

Standalone Net Profit

25.77

26.87

-4.09%

Operating Profit Margin (Excl OI)

36.04%

32.80%

3.24%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -11.20% vs 2.73% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is -4.09% vs -9.65% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

168.06

168.40

-0.20%

Operating Profit (PBDIT) excl Other Income

61.27

60.03

2.07%

Interest

3.47

1.99

74.37%

Exceptional Items

0.00

Standalone Net Profit

54.95

41.98

30.90%

Operating Profit Margin (Excl OI)

36.46%

35.65%

0.81%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

258.34

251.88

2.56%

Operating Profit (PBDIT) excl Other Income

90.88

86.49

5.08%

Interest

4.10

3.24

26.54%

Exceptional Items

0.00

Standalone Net Profit

81.82

62.61

30.68%

Operating Profit Margin (Excl OI)

35.18%

34.34%

0.84%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

642.26

502.00

27.94%

Operating Profit (PBDIT) excl Other Income

221.91

189.95

16.83%

Interest

7.60

5.85

29.91%

Exceptional Items

0.00

Consolidate Net Profit

172.89

138.73

24.62%

Operating Profit Margin (Excl OI)

34.55%

37.84%

-3.29%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025

All Annual Results

Company CV

About Sudeep Pharma Ltd

Sudeep Pharma Ltd

Small Cap

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available